RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Carna Biosciences Stock

Carna Biosciences P/E 2025

Carna Biosciences P/E

2

Ticker

4572.T

ISIN

JP3220550002

WKN

A0NHD5

As of Jan 23, 2025, Carna Biosciences's P/E ratio was 2, a -29.33% change from the 2.83 P/E ratio recorded in the previous year.

The Carna Biosciences P/E history

Carna Biosciences Aktienanalyse

What does Carna Biosciences do?

Carna Biosciences Inc is a biopharmaceutical company focused on the development, manufacturing, and marketing of innovative drugs for the treatment of serious diseases. The company was founded in Kobe, Japan in 2003 and has quickly become a major player in biomedical research and development. Carna Biosciences Inc's business model is based on the development and marketing of drugs developed through advanced scientific technologies and procedures. The company aims to provide groundbreaking treatments that meet the needs of patients and improve their quality of life. Carna Biosciences has three different business areas focusing on the discovery, development, and manufacturing of therapeutics. The first area is drug research, where the company identifies and characterizes new drug candidates. The second area is drug development, where the company further develops potential drug candidates and conducts clinical trials. The third area is drug manufacturing and marketing, where Carna Biosciences advances the approval and commercialization of drugs in Japan, the United States, and Europe. Carna Biosciences offers a variety of products that can be used for the development of new drugs and research in the fields of biology and pharmacology. These products include kinase inhibitors, proteins, antibodies, enzymes, and reagents for cell analysis. Of particular note are the company's high-quality kinase inhibitors, which can be used for the research of cancer and other diseases. Kinase inhibitors are drugs that inhibit cell growth by blocking the enzyme kinase, which is responsible for cell growth and division. Carna Biosciences has developed a range of kinase inhibitors that show promise in the treatment of cancer, neurodegenerative diseases, and inflammation. Important milestones in the company's history include the establishment of Carna Biosciences USA, Inc. in 2016, further expanding the company's presence in the North American market. Additionally, Carna Biosciences has formed several partnerships with other companies to advance the development and marketing of new therapeutics. Overall, Carna Biosciences has become a major player in the biopharmaceutical industry focused on the development of innovative drugs to combat serious diseases. The company relies on cutting-edge scientific technologies and procedures to develop groundbreaking treatments and improve the quality of life for patients worldwide. Carna Biosciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

P/E Details

Deciphering Carna Biosciences's P/E Ratio

The Price to Earnings (P/E) Ratio of Carna Biosciences is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.

Year-to-Year Comparison

Assessing Carna Biosciences's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.

Impact on Investments

The P/E ratio of Carna Biosciences is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.

Interpreting P/E Ratio Fluctuations

Fluctuations in Carna Biosciences’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.

Frequently Asked Questions about Carna Biosciences stock

What is the price-to-earnings ratio of Carna Biosciences?

The price-earnings ratio of Carna Biosciences is currently 2.

How has the price-earnings ratio of Carna Biosciences changed compared to last year?

The price-to-earnings ratio of Carna Biosciences has increased by -29.33% fallen (meaning "decreased" or "dropped") compared to last year.

What consequences does a high price-earnings ratio have for investors?

A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.

What does a low price-earnings ratio mean?

A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.

Is the price-earnings ratio of Carna Biosciences high compared to other companies?

Yes, the price-to-earnings ratio of Carna Biosciences is high compared to other companies.

How does an increase in the price-earnings ratio of Carna Biosciences affect the company?

An increase in the price-earnings ratio of Carna Biosciences would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.

How does a reduction in the price-to-earnings ratio of Carna Biosciences affect the company?

A decrease in the price-earnings ratio of Carna Biosciences would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.

What are some factors that influence the price-earnings ratio of Carna Biosciences?

Some factors that influence the price-earnings ratio of Carna Biosciences are the company's growth, financial position, industry development, and the overall economic situation.

How much dividend does Carna Biosciences pay?

Over the past 12 months, Carna Biosciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Carna Biosciences is expected to pay a dividend of 0 JPY.

What is the dividend yield of Carna Biosciences?

The current dividend yield of Carna Biosciences is .

When does Carna Biosciences pay dividends?

Carna Biosciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Carna Biosciences?

Carna Biosciences paid dividends every year for the past 0 years.

What is the dividend of Carna Biosciences?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is Carna Biosciences located?

Carna Biosciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Carna Biosciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Carna Biosciences from 1/23/2025 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 1/23/2025.

When did Carna Biosciences pay the last dividend?

The last dividend was paid out on 1/23/2025.

What was the dividend of Carna Biosciences in the year 2024?

In the year 2024, Carna Biosciences distributed 0 JPY as dividends.

In which currency does Carna Biosciences pay out the dividend?

The dividends of Carna Biosciences are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Carna Biosciences

Our stock analysis for Carna Biosciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Carna Biosciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.